EG 427French targeted DNA gene therapy specialist EG427 has closed a €27m Series B financing co-led by VC investor Andera Partners and BPI France to initiate Phase I testing of a Herpes Simplex Virus 1 (nrHSV-1) vector that specifically targets type C neurons to suppress dysfunctions of the bladder in people with spinal injury.
Tag Archive for: EG 427
Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.